- Home
- LITM vs SCYX Comparison
LITM vs SCYX Comparison
Compare LITM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITM
- SCYX
- Stock Information
- Founded
- LITM 2018
- SCYX 1999
- Country
- LITM Canada
- SCYX United States
- Employees
- LITM N/A
- SCYX N/A
- Industry
- LITM Other Metals and Minerals
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- LITM Basic Materials
- SCYX Health Care
- Exchange
- LITM Nasdaq
- SCYX Nasdaq
- Market Cap
- LITM 42.2M
- SCYX 40.9M
- IPO Year
- LITM 2021
- SCYX 2014
- Fundamental
- Price
- LITM $0.41
- SCYX $0.90
- Analyst Decision
- LITM
- SCYX
- Analyst Count
- LITM 0
- SCYX 0
- Target Price
- LITM N/A
- SCYX N/A
- AVG Volume (30 Days)
- LITM 10.0M
- SCYX 94.5K
- Earning Date
- LITM 04-29-2025
- SCYX 05-07-2025
- Dividend Yield
- LITM N/A
- SCYX N/A
- EPS Growth
- LITM N/A
- SCYX N/A
- EPS
- LITM N/A
- SCYX N/A
- Revenue
- LITM N/A
- SCYX $3,746,000.00
- Revenue This Year
- LITM N/A
- SCYX $460.12
- Revenue Next Year
- LITM N/A
- SCYX $253.87
- P/E Ratio
- LITM N/A
- SCYX N/A
- Revenue Growth
- LITM N/A
- SCYX N/A
- 52 Week Low
- LITM $0.15
- SCYX $0.73
- 52 Week High
- LITM $1.88
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- LITM 41.02
- SCYX 45.97
- Support Level
- LITM $0.39
- SCYX $0.89
- Resistance Level
- LITM $0.55
- SCYX $0.99
- Average True Range (ATR)
- LITM 0.06
- SCYX 0.08
- MACD
- LITM -0.00
- SCYX 0.01
- Stochastic Oscillator
- LITM 16.46
- SCYX 64.71
About LITM Snow Lake Resources Ltd.
Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.